Rafael Holdings, Inc. (NYSE:RFL – Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totaling 52,381 shares, a growth of 30.1% from the December 15th total of 40,257 shares. Based on an average daily trading volume, of 171,579 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company’s stock are sold short. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 171,579 shares, the short-interest ratio is presently 0.3 days.
Rafael Stock Performance
NYSE RFL traded up $0.01 on Monday, hitting $1.25. 41,107 shares of the stock traded hands, compared to its average volume of 96,071. The business’s fifty day moving average is $1.26 and its two-hundred day moving average is $1.46. Rafael has a 12 month low of $1.12 and a 12 month high of $3.19. The firm has a market capitalization of $64.71 million, a price-to-earnings ratio of -1.47 and a beta of 0.67.
Rafael (NYSE:RFL – Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.28) EPS for the quarter. Rafael had a negative net margin of 3,044.70% and a negative return on equity of 32.82%. The firm had revenue of $0.89 million for the quarter.
Institutional Trading of Rafael
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Rafael in a report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.
Check Out Our Latest Report on Rafael
About Rafael
Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.
Read More
- Five stocks we like better than Rafael
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
Receive News & Ratings for Rafael Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rafael and related companies with MarketBeat.com's FREE daily email newsletter.
